Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MEGACE | Bristol Myers Squibb | N-020264 DISCN | 1993-09-10 | 1 products, RLD |
MEGACE | Bristol Myers Squibb | N-016979 DISCN | 1982-01-01 | 2 products, RLD |
MEGACE ES | Endo | N-021778 DISCN | 2005-07-05 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
megace es | New Drug Application | 2014-03-18 |
megestol | ANDA | 2010-01-22 |
megestrol acetate | ANDA | 2025-05-23 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
endometrial neoplasms | EFO_0004230 | D016889 | — |
cachexia | — | D002100 | R64 |
anorexia | — | D000855 | R63.0 |
Code | Description |
---|---|
S0179 | Megestrol acetate, oral, 20 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cachexia | D002100 | — | R64 | 2 | 11 | 9 | 3 | 2 | 26 |
Wasting syndrome | D019282 | — | — | 1 | 10 | 9 | 1 | 2 | 22 |
Anorexia | D000855 | — | R63.0 | 1 | 9 | 8 | 2 | — | 19 |
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 3 | 1 | 1 | 2 | 8 |
Esophageal neoplasms | D004938 | — | C15 | — | — | 1 | 1 | — | 2 |
Second primary neoplasms | D016609 | — | — | — | — | — | 1 | — | 1 |
Feeding and eating disorders | D001068 | — | F50 | — | — | — | 1 | — | 1 |
Feeding behavior | D005247 | — | — | — | — | — | 1 | — | 1 |
Feeding and eating disorders of childhood | D019959 | — | — | — | — | — | 1 | — | 1 |
Precocious puberty | D011629 | — | E22.8 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 18 | 4 | — | 3 | 24 |
Hyperplasia | D006965 | EFO_0000536 | — | — | 13 | 7 | — | 2 | 16 |
Neoplasms | D009369 | — | C80 | — | 9 | 5 | — | 2 | 15 |
Endometrial hyperplasia | D004714 | — | N85.0 | — | 12 | 7 | — | 2 | 15 |
Carcinoma | D002277 | — | C80.0 | — | 7 | 4 | — | 1 | 11 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 5 | 2 | — | — | 7 |
Endometrioid carcinoma | D018269 | — | — | 1 | 4 | 1 | — | 3 | 7 |
Weight loss | D015431 | — | — | — | 4 | 4 | — | — | 7 |
Lung neoplasms | D008175 | — | C34.90 | — | 2 | 4 | — | — | 6 |
Infertility | D007246 | EFO_0000545 | — | — | 4 | 3 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Syndrome | D013577 | — | — | 1 | 5 | — | — | 1 | 7 |
Hiv wasting syndrome | D019247 | EFO_0007312 | — | 1 | 2 | — | — | 1 | 4 |
Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | 2 | — | — | 1 | 3 |
Adenocarcinoma | D000230 | — | — | 1 | 2 | — | — | 1 | 3 |
Recurrence | D012008 | — | — | 1 | 3 | — | — | — | 3 |
Carcinoma in situ | D002278 | — | D09.9 | — | 2 | — | — | — | 2 |
Fatigue | D005221 | — | R53.83 | — | 1 | — | — | 1 | 2 |
Vomiting | D014839 | — | R11.1 | — | 1 | — | — | — | 1 |
Nausea | D009325 | — | R11.0 | — | 1 | — | — | — | 1 |
Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | 1 | 3 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Absorption | D000042 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | — | — | — | — | 3 | 3 |
Fertility preservation | D059247 | — | — | — | — | — | — | 2 | 2 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 2 | 2 |
Adrenal insufficiency | D000309 | — | — | — | — | — | — | 1 | 1 |
Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | — | — | 1 | 1 |
Failure to thrive | D005183 | — | — | — | — | — | — | 1 | 1 |
Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
Conservative treatment | D000072700 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Megestrol acetate |
INN | megestrol |
Description | Megestrol acetate is a steroid ester resulting from the formal condensation of the hydroxy group of megestrol with the carboxy group of acetic acid. It is an appetite stimulant used for the treatment of anorexia and cachexia. Also used for birth control and for the treatment of breast cancer. It has a role as an antineoplastic agent, an appetite enhancer, a contraceptive drug, a progestin and a synthetic oral contraceptive. It is a steroid ester, an acetate ester, a 20-oxo steroid and a 3-oxo-Delta(4) steroid. It is functionally related to a megestrol. |
Classification | Small molecule |
Drug class | estrogens; progestins |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C |
PDB | — |
CAS-ID | 595-33-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1201139 |
ChEBI ID | — |
PubChem CID | 11683 |
DrugBank | DB00351 |
UNII ID | EA6LD1M70M (ChemIDplus, GSRS) |